The Mitophagy Company
Targeting mitochondrial biology to power therapeutic breakthroughs
Mitophagy is the evolutionarily conserved process by which dysfunctional mitochondria are tagged, removed, and replaced in cells.
Mitochondria are dynamic organelles that undergo constant cycles of fission (division of one mitochondria) and fusion (combining of two mitochondria). In a healthy cell, this process helps to segregate old, dysfunctional mitochondria from functional ones. Dysfunctional mitochondria are tagged for degradation and recycling. Engulfment of tagged mitochondria by an autophagosome and subsequent fusion with an acidic lysosome leads to activation of enzymes that break down and recycle the mitochondria. Importantly, removal of mitochondria by mitophagy triggers mitochondrial biogenesis and maintenance of the optimal mitochondrial mass specific for each cell type.
During aging or disease, the ability of the cell to identify or process dysfunctional mitochondria is deficient. The accumulation of energetically suboptimal mitochondria inside each cell leads to release of reactive oxygen species (ROS) and inflammatory signals such as cytochrome c and mtDNA, calcium dysregulation, decreased ATP production, and cell death.
While the importance of mitophagy in human health and disease is well established, strategies to safely and effectively target mitophagy remain challenging. Capacity Bio’s proprietary approach is to develop small molecules, peptides, and nanoparticles that enhance identification of dysfunctional mitochondria, activate mitophagy pathways, and promote clearance by autophagosomes and lysosomes.
Jonas Hannestad, MD, PhD
Brian Kearney, PharmD
Shirin Arastu Kapur, PhD
Amy Wang, PhD
Kevin Gaffney, PhD
Karel Erion, PhD
Lada Klaic, PhD
Matheus Oliveira, PhD
Anton Petcherski, PhD
Stan Louie, PharmD
Professor of Clinical Pharmacy, Director of Clinical Experimental Therapeutics Program, USC
Kathleen Rodgers, PhD
Associate Director, Translational Neuroscience, Center for Innovations in Brain Science; Professor of Pharmacology, University of Arizona
Orian Shirihai, MD, PhD
Professor of Medicine and Molecular and Medical Pharmacology, UCLA
Board of Directors
Aiden Aceves, PhD
Andrew Levin, MD, PhD
Rebecca Silberman, PhD
Amy Wang, PhD
$35M Financing to Advance Mitophagy Platform
Capacity Bio, Inc., a mitochondria-focused biotechnology company developing novel mitophagy modulators, announced today the close of a $35 million financing round. Leading life science investor RA Capital Management and Insight Partners co-led the financing and joined existing investor Remiges Ventures to support the acceleration of Capacity Bio’s first-in-class mitophagy agonist and is expected to enter clinical trials in 2024. The financing will also advance Capacity’s preclinical programs focused on new mitochondrial modulators.